Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesEndocrinologyCigna Thyroid RFA Coverage Policy Update | OpenPay…
    Ask Trek AI about this page
    CurrentCignaPolicy 0575

    Radiofrequency Ablation for Thyroid Nodules

    Customize your policy alerts

    Sign up for Cigna Policy 0575 alerts

    Get alerted when Policy 0575 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of percutaneous radiofrequency ablation (RFA) for thyroid nodules under Cigna-administered health benefit plans. Coverage applies when the thyroid condition and treatment circumstances meet the medical-necessity criteria and applicable benefit-plan requirements.

    Policy Summary
    PayerCigna
    PolicyRadiofrequency Ablation for Thyroid Nodules
    Policy CodePolicy 0575
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 15, 2026
    Next Review DateOctober 15, 2027
    Key ActionFor benign thyroid nodules, verify compressive symptoms and limit treatment to a single RFA treatment in a 12-month period.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Covered clinical indication categories
    1 per 12 monthsMaximum RFA treatments for a benign thyroid nodule
    2CPT codes listed for thyroid nodule RFA
    No clinical changesFinding documented for the annual and focused reviews

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medical Necessity and Evidence

    Medically necessary indications

    RFA is considered medically necessary when ANY of the following criteria groups is met.

    Covered indications

    • Differentiated thyroid cancer: Treatment of differentiated thyroid cancer, including papillary, follicular, or oncocytic carcinoma (formerly known as Hürthle cell carcinoma).
    • Medullary thyroid cancer: Treatment of medullary thyroid cancer.
    • Autonomously functioning nodule: Treatment of an autonomously functioning thyroid nodule as treatment for hyperthyroidism.

    • Benign thyroid nodule

      • Compressive symptoms: The benign thyroid nodule causes compressive symptoms, such as changes of voice, dysphagia, dyspnea, or pain.

        Examples listed in the policy include changes of voice, dysphagia, dyspnea, and pain.

      • Treatment frequency limitation: Treatment is limited to a single RFA treatment in a 12-month period.1 RFA treatment per 12 months

    Published professional-society indications and considerations

    Published guidance describes the following potential indications and treatment considerations:

    Benign symptomatic or cosmetically concerning nodule: Ultrasound-guided thermal ablation, including RFA, may be considered for a benign solid or complex thyroid nodule that progressively enlarges, causes compressive symptoms, or causes cosmetic concern.

    AACE/ACE/AME and international consensus recommendations; not stated as a Cigna authorization rule.

    Autonomously functioning nodule: Thermal ablation may be considered for an autonomously functioning thyroid nodule when first-line surgery or radioactive iodine is contraindicated or unsuitable; it is less efficacious than surgery or radioactive iodine for normalizing thyroid function.

    Professional consensus and society guidance; AAES does not recommend this as initial treatment for toxic adenoma in the United States.

    Selected papillary microcarcinoma: Ultrasound-guided ablation may be considered for suitable primary papillary microcarcinoma in patients who are unfit for surgery or who decline surgery or active surveillance.

    International consensus statement; not stated as a Cigna authorization rule.

    Evidence limitations

    The literature identifies the following limitations:

    Evidence remains limited for indeterminate nodules and several malignant applications: Further investigation is needed regarding the role of thermal ablation in indeterminate nodules, primary malignancy, metastatic disease, comparative treatment selection, long-term efficacy, retreatment timing, and training requirements.

    The cited prospective study authors characterized RFA for indeterminate nodules as a potential option requiring larger samples and longer follow-up.

    Covered Codes and Treatment Limits

    Covered CPT CodesCPTCovered
    60660Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency.
    60661Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)
    Benign thyroid nodule RFA frequency
    Applies toBenign thyroid nodule treatment with RFA
    Frequency limitA single RFA treatment in a 12-month period
    Additional coverage conditionThe benign thyroid nodule must cause compressive symptoms, such as changes of voice, dysphagia, dyspnea, or pain

    Coverage and Denial Considerations

    Denial Risk

    Avoid denial: confirm indication and criteria

    Coverage may be denied when RFA is requested for a condition outside the covered indications. For a benign thyroid nodule, both compressive symptoms and the limitation to a single RFA treatment in a 12-month period must be met; claims may also be denied when submitted without applicable covered procedure or diagnosis codes.

    • Covered indications are differentiated thyroid cancer, medullary thyroid cancer, autonomously functioning nodules treated for hyperthyroidism, or a benign thyroid nodule meeting both criteria.
    • For a benign thyroid nodule, document compressive symptoms such as changes of voice, dysphagia, dyspnea, or pain.
    • Limit treatment to a single RFA treatment in a 12-month period.
    • Submit the applicable covered procedure and diagnosis codes; claims without covered codes will be denied as not covered.

    Clinical Background

    Radiofrequency ablation (RFA) applies radiofrequency waves to thyroid nodule tissue, producing thermal injury and necrosis. The treated tissue is gradually reabsorbed, resulting in an overall reduction in nodule volume.

    The policy addresses RFA as a minimally invasive treatment option for differentiated thyroid cancer, medullary thyroid cancer, autonomously functioning nodules causing hyperthyroidism, and selected benign thyroid nodules with compressive symptoms. RFA is operator-dependent and should be performed in centers with specific expertise.

    Policy Terms and Clinical Concepts

    Radiofrequency ablation (RFA)
    Treatment mechanismApplication of radiofrequency waves to thyroid nodule tissue
    Tissue responseRadiofrequency waves cause thermal injury and subsequent necrosis of the tissue
    ResultGradual reabsorption of ablated tissue produces overall thyroid nodule volume reduction
    Autonomously functioning nodules
    DefinitionThyroid nodules that function autonomously
    Clinical useMay be treated with RFA for hyperthyroidism
    Reported outcome
    Policy Summary
    PayerCigna
    PolicyRadiofrequency Ablation for Thyroid Nodules
    Policy CodePolicy 0575
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 15, 2026
    Next Review DateOctober 15, 2027
    Key ActionFor benign thyroid nodules, verify compressive symptoms and limit treatment to a single RFA treatment in a 12-month period.
    SourceLink
    On This Page
    Medical Necessity and EvidenceCovered Codes and Treatment LimitsCoverage and Denial ConsiderationsClinical BackgroundPolicy Terms and Clinical Concepts

    Pre-treatment evaluation for benign nodules

    • Cytologic confirmation: Repeat fine-needle aspiration for cytologic confirmation before thermal ablation treatment.
    • Informed discussion: Discuss alternative therapy options and their efficacy, limitations, and adverse effects with the patient.
    A systematic review reported a 76.4% overall rate of TSH normalization after RFA
    Differentiated thyroid cancer
    Included typePapillary carcinoma
    Included typeFollicular carcinoma
    Included type and terminologyOncocytic carcinoma, formerly known as Hürthle cell carcinoma
    Indeterminate thyroid nodule
    DefinitionA thyroid nodule classified as Bethesda III or IV by cytopathology
    Benign categoryBethesda II is classified as benign
    Excluded categories in the cited studyBethesda V and VI nodules were excluded
    Autonomously functioning thyroid nodule (AFTN)
    DefinitionA benign thyroid nodule with autonomous function
    Alternative treatment contextProfessional guidance discusses RFA as an alternative to surgery or radioactive iodine treatment
    Guidance contextRFA may be considered for selected autonomously functioning or toxic nodules
    Technique efficacy
    DefinitionReduction of at least 50% in nodule volume one year after treatment
    RFA result in the cited studyTechnique efficacy was achieved in 85% of patients treated with RFA
    Comparison resultTechnique efficacy was achieved in 63% of patients treated with laser ablation
    Health equity and health inequity
    Health equityThe highest level of health for all people
    Health inequityAn avoidable difference in health status or distribution of health resources
    Underlying social conditionsConditions in which people are born, grow, live, work, and age
    Social determinants of health
    DefinitionConditions in the environment that affect a wide range of health, functioning, and quality-of-life outcomes and risks
    ExamplesSafe housing, transportation, neighborhoods, education, job opportunities, and income
    Additional examplesRacism, discrimination, violence, access to nutritious foods and physical activity opportunities, clean air and water, and language and literacy skills